JAJanuka S. Athukoralage

Januka S. Athukoralage

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Januka S. Athukoralage has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prokaryotic homologs of the major vault protein form engineerable vault nanocapsules

    by Januka S. Athukoralage, Peter H. Yoon, Amir Shanehsazzadeh, Eric Kauderer-Abrams, Nicholas T. Perry, Matthew G. Durrant

    Vaults are the largest ribonucleoprotein particles in eukaryotic cells, built from 78 copies of the major vault protein (MVP), yet their function remains unknown four decades after their discovery. MVP homologs occur in prokaryotes and bacteriophages, but whether they form vaults is unknown. Here, we show that prokaryotic and bacteriophage MVP homologs assemble into vault particles. We surveyed approximately 15 billion proteins, found MVP homologs in 29 bacterial and 4 archaeal phyla, and used size-exclusion chromatography to rapidly screen and isolate vault particles of eight homologs expressed in Escherichia coli . Cryo-electron microscopy structures of the phage homolog L05 at high resolution reveal a shell of 96 MVP chains enclosing a volume ∼25% larger than human vaults, among the largest protein shells of defined size outside virus capsids. Prokaryotic MVPs typically carry seven wall repeats and eukaryotic MVPs nine, and adding wall repeats to L05 yields larger vaults. Prokaryotic vaults expand the known diversity of vault architecture and offer a tractable system for studying vault assembly and a size-tunable scaffold for cargo encapsulation.

  • Open Access

    Autonomous AI agents discover reverse transcriptases with tandem repeat arrays

    by Peter H. Yoon, Januka S. Athukoralage, Emmanuel Ameisen, Eric Kauderer-Abrams, Nicholas T. Perry, Matthew G. Durrant

    Metagenomic databases hold vast quantities of unexplored genetic material that can seed tools for biotechnology and medicine, but discovery is limited by our ability to examine sequence data at scale. Here, we show that large language models (LLMs) in an autonomous harness can alleviate this bottleneck and surface novel molecular systems. We deployed Claude Code instances to survey reverse transcriptase (RT) loci across 1.9 billion protein clusters. Among the top candidates were array-associated RTs (ART), a novel family of jumbo-phage RTs coupled with an array of ∼200-nucleotide units and a dedicated partner gene. Session transcripts show that Claude identified the ART family by directly examining its DNA sequences and recognizing the atypical repeats, a behavior attributable to specific Mythos 5 internal signals that respond to repeated DNA. ART arrays are highly expressed and appear as discrete units during Staphylococcus phage infection, suggesting an RT system directed by a repertoire of distinct RNAs. These findings indicate that LLMs can autonomously detect anomalies and drive analyses to initiate biological discoveries.


  • Open Access

    Activation of Csm6 ribonuclease by cyclic nucleotide binding: in an emergency, twist to open

    by Stuart McQuarrie, Januka S Athukoralage, Stephen A McMahon, Shirley Graham, Katrin Ackermann, Bela E Bode, Malcolm F White, Tracey M Gloster

    Type III CRISPR systems synthesize cyclic oligoadenylate (cOA) second messengers as part of a multi-faceted immune response against invading mobile genetic elements (MGEs). cOA activates non-specific CRISPR ancillary defence nucleases to create a hostile environment for MGE replication. Csm6 ribonucleases bind cOA using a CARF (CRISPR-associated Rossmann Fold) domain, resulting in activation of a fused HEPN (Higher Eukaryotes and Prokaryotes Nucleotide binding) ribonuclease domain. Csm6 enzymes are widely used in a new generation of diagnostic assays for the detection of specific nucleic acid species. However, the activation mechanism is not fully understood. Here we characterised the cyclic hexa-adenylate (cA6) activated Csm6’ ribonuclease from the industrially important bacterium Streptococcus thermophilus. Crystal structures of Csm6’ in the inactive and cA6 bound active states illuminate the conformational changes which trigger mRNA destruction. Upon binding of cA6, there is a close to 60° rotation between the CARF and HEPN domains, which causes the ‘jaws’ of the HEPN domain to open and reposition active site residues. Key to this transition is the 6H domain, a right-handed solenoid domain connecting the CARF and HEPN domains, which transmits the conformational changes for activation.


  • Open Access

    Bacteriophages antagonize cGAS-like immunity in bacteria

    by Erin Huiting, Januka Athukoralage, Jingwen Guan, Sukrit Silas, Héloïse Carion, Joseph Bondy-Denomy

    Summary: The recently discovered c yclic-oligonucleotide- b ased a nti-phage s ignaling s ystem (CBASS) is related to eukaryotic cGAS-STING anti-viral immunity and is present in diverse prokaryotes. However, our understanding of how CBASS detects, inhibits, and co-evolves with phages is limited because CBASS function has only been studied in reconstituted heterologous systems. Here, we identify a phage-encoded CBASS antagonist ( acbIIA1, a nti- cb ass type II-A gene 1 ) necessary for phage replication in the presence of endogenous CBASS immunity in Pseudomonas aeruginosa . acbIIA1 homologs are encoded by numerous lytic and temperate phages infecting Gram-negative bacteria. Deletion of acbIIA1 renders multiple phages susceptible to CBASS, but phages can then escape immune function via mutations in the major capsid gene. These mutants suggest that CBASS is activated by, or targets, the late-expressed phage capsid. Together, we establish a native model system to study CBASS and identify a common phage-encoded CBASS antagonist, demonstrating that CBASS is a bona fide anti-phage immune system in nature. Graphical


  • Open Access

    Cyclic oligoadenylate signaling and regulation by ring nucleases during type III CRISPR defense

    by Januka S. Athukoralage, Malcolm F. White

    In prokaryotes, CRISPR-Cas immune systems recognize and cleave foreign nucleic acids to defend against mobile genetic elements (MGEs). Type III CRISPR-Cas complexes also synthesize cyclic oligoadenylate (cOA) second messengers, which activate CRISPR ancillary proteins involved in antiviral defense. In particular, cOA-stimulated nucleases degrade RNA and DNA nonspecifically, which slows MGE replication but also impedes cell growth, necessitating mechanisms to eliminate cOA in order to facilitate cell recovery. Extant cOA is degraded by a new class of enzyme termed a “ring nuclease,” which cleaves cOA specifically and switches off CRISPR ancillary enzymes. Several ring nuclease families have been characterized to date, including a family used by MGEs to circumvent CRISPR immunity, and encompass diverse protein folds and distinct cOA cleavage mechanisms. In this review we examine cOA signaling, discuss how different ring nucleases regulate the cOA signaling pathway, and reflect on parallels between cyclic nucleotide-based immune systems to reveal new areas for exploration.


  • Open Access

    Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage

    by Januka S Athukoralage, Stuart McQuarrie, Sabine Grüschow, Shirley Graham, Tracey M Gloster, Malcolm F White

    Type III CRISPR systems detect foreign RNA and activate the cyclase domain of the Cas10 subunit, generating cyclic oligoadenylate (cOA) molecules that act as a second messenger to signal infection, activating nucleases that degrade the nucleic acid of both invader and host. This can lead to dormancy or cell death; to avoid this, cells need a way to remove cOA from the cell once a viral infection has been defeated. Enzymes specialised for this task are known as ring nucleases, but are limited in their distribution. Here, we demonstrate that the widespread CRISPR associated protein Csx3, previously described as an RNA deadenylase, is a ring nuclease that rapidly degrades cyclic tetra-adenylate (cA4). The enzyme has an unusual cooperative reaction mechanism involving an active site that spans the interface between two dimers, sandwiching the cA4 substrate. We propose the name Crn3 (CRISPR associated ring nuclease 3) for the Csx3 family.


  • Open Access

    Fuse to defuse: a self-limiting ribonuclease-ring nuclease fusion for type III CRISPR defence

    by Aleksei Samolygo, Januka S Athukoralage, Shirley Graham, Malcolm F White

    Type III CRISPR systems synthesise cyclic oligoadenylate (cOA) second messengers in response to viral infection of bacteria and archaea, potentiating an immune response by binding and activating ancillary effector nucleases such as Csx1. As these effectors are not specific for invading nucleic acids, a prolonged activation can result in cell dormancy or death. Some archaeal species encode a specialised ring nuclease enzyme (Crn1) to degrade cyclic tetra-adenylate (cA4) and deactivate the ancillary nucleases. Some archaeal viruses and bacteriophage encode a potent ring nuclease anti-CRISPR, AcrIII-1, to rapidly degrade cA4 and neutralise immunity. Homologues of this enzyme (named Crn2) exist in type III CRISPR systems but are uncharacterised. Here we describe an unusual fusion between cA4-activated CRISPR ribonuclease (Csx1) and a cA4-degrading ring nuclease (Crn2) from Marinitoga piezophila. The protein has two binding sites that compete for the cA4 ligand, a canonical cA4-activated ribonuclease activity in the Csx1 domain and a potent cA4 ring nuclease activity in the C-terminal Crn2 domain. The cA4 binding affinities and activities of the two constituent enzymes in the fusion protein may have evolved to ensure a robust but time-limited cOA-activated ribonuclease activity that is finely tuned to cA4 levels as a second messenger of infection.


  • Open Access

    Tetramerisation of the CRISPR ring nuclease Csx3 facilitates cyclic oligoadenylate cleavage

    by Januka S. Athukoralage, Stuart McQuarrie, Sabine Grüschow, Shirley Graham, Tracey M. Gloster, Malcolm F. White

    Type III CRISPR systems detect foreign RNA and activate the cyclase domain of the Cas10 subunit, generating cyclic oligoadenylate (cOA) molecules that act as a second messenger to signal infection, activating nucleases that degrade the nucleic acid of both invader and host. This can lead to dormancy or cell death; to avoid this, cells need a way to remove cOA from the cell once a viral infection has been defeated. Enzymes specialised for this task are known as ring nucleases, but are limited in their distribution. Here, we demonstrate that the widespread CRISPR associated protein Csx3, previously described as an RNA deadenylase, is a ring nuclease that rapidly degrades cyclic tetra-adenylate (cA 4 ). The enzyme has an unusual cooperative reaction mechanism involving an active site that spans the interface between two dimers, sandwiching the cA 4 substrate. We propose the name Crn3 (CRISPR associated ring nuclease 3) for the Csx3 family.


  • Open Access

    The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling

    by Januka S Athukoralage, Shirley Graham, Christophe Rouillon, Sabine Grüschow, Clarissa M Czekster, Malcolm F White

    Cyclic nucleotide second messengers are increasingly implicated in prokaryotic anti-viral defence systems. Type III CRISPR systems synthesise cyclic oligoadenylate (cOA) upon detecting foreign RNA, activating ancillary nucleases that can be toxic to cells, necessitating mechanisms to remove cOA in systems that operate via immunity rather than abortive infection. Previously, we demonstrated that the Sulfolobus solfataricus type III-D CRISPR complex generates cyclic tetra-adenylate (cA4), activating the ribonuclease Csx1, and showed that subsequent RNA cleavage and dissociation acts as an ‘off-switch’ for the cyclase activity. Subsequently, we identified the cellular ring nuclease Crn1, which slowly degrades cA4 to reset the system (Rouillon et al., 2018), and demonstrated that viruses can subvert type III CRISPR immunity by means of a potent anti-CRISPR ring nuclease variant AcrIII-1. Here, we present a comprehensive analysis of the dynamic interplay between these enzymes, governing cyclic nucleotide levels and infection outcomes in virus-host conflict.


  • Open Access

    Fuse to defuse: a self-limiting ribonuclease-ring nuclease fusion for type III CRISPR defence

    by Aleksei Samolygo, Januka S. Athukoralage, Shirley Graham, Malcolm F. White

    Type III CRISPR systems synthesise cyclic oligoadenylate (cOA) second messengers in response to viral infection of bacteria and archaea, potentiating an immune response by binding and activating ancillary effector nucleases such as Csx1. As these effectors are not specific for invading nucleic acids, a prolonged activation can result in cell dormancy or death. To avoid this fate, some archaeal species encode a specialised ring nuclease enzyme (Crn1) to degrade cyclic tetra-adenylate (cA 4 ) and deactivate the ancillary nucleases. Some archaeal viruses and bacteriophage encode a potent ring nuclease anti-CRISPR, AcrIII-1, to rapidly degrade cA 4 and neutralise immunity. Homologues of this enzyme (named Crn2) exist in type III CRISPR systems but are uncharacterised. Here we describe an unusual fusion between cA 4 -activated CRISPR ribonuclease (Csx1) and a cA 4 -degrading ring nuclease (Crn2) from Marinitoga piezophila . The protein has two binding sites that compete for the cA 4 ligand, a canonical cA 4 -activated ribonuclease activity in the Csx1 domain and a potent cA 4 ring nuclease activity in the C-terminal Crn2 domain. The activities of the two constituent enzymes in the fusion protein cooperate to ensure a robust but time-limited cOA-activated ribonuclease activity that is finely tuned to cA 4 levels as a second messenger of infection.